Patricia S. Walker, MD, PhD (Dermatologist)
Dr. Patricia S. Walker is a board-certified dermatologist and industry expert specializing in the fields of medical and aesthetic dermatology. She has been in clinical practice for more than 17 years, serving as Chief Medical Officer for Kythera Biopharmaceuticals, Inc. and Executive Vice President and Chief Science Officer for Allergan Medical Aesthetics.
Over the past 10 years, she has led key product approvals in dermatology, including the development and approval of Tazorac®, Botox® Cosmetic, Juvederm™, Hylaform®, Captique®, LAP-BAND® and Inamed® Silicone gel-filled breast implants.
Dr. Walker received her medical degree from the University of Iowa College of Medicine. She completed an internship in internal medicine at the University of Minnesota College of Medicine, residency training in dermatology at the University of Iowa College of Medicine and completed a fellowship at the National Institute of Health’s Dermatology Branch. She is certified by the American Board of Dermatology, has been a Committee Member for the American Academy of Dermatology (AAD) and is a member of the American Dermatologic Association and holds medical licenses in Iowa and California.
Michael B. Chancellor, MD (Urologist)
Dr. Michael B. Chancellor, board-certified by the American Board of Urology, received his medical degree from Medical College of Wisconsin in Milwaukee. Dr. Chancellor completed his residency in urology at the University of Michigan in Ann Arbor. He subsequently completed his fellowship in neurology and female urology at Columbia University and College of Physicians and Surgeons in New York. Dr. Chancellor is a world-renowned author and speaker, and has been invited to present more than 650 papers at national and international meetings. He has appeared on CNN, in the pages of The Wall Street Journal, and in numerous television and radio interviews.
Dr. Chancellor has written more than 550 peer-reviewed articles and book chapters in journals including The Journal of Urology, Urology, Gene Therapy, and Lancet. He has also written 11 books and serves on the editorial board of 12 scientific journals. A prolific author and researcher, Dr. Chancellor has gained national and international recognition in the areas of stem cell and tissue engineering as well as drug discovery. He was the first urologist to use botulinum toxin to treat lower urinary tract dysfunction. His inventions founded Cook MyoSite, Inc., which is now conducting multicenter North American trials using adult autologous muscle-derived stem cells to treat stress urinary incontinence. Dr. Chancellor is also founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc.
Kurt C. Gunter, MD, FASCP (Chief Medical Officer, CellMedica)
Dr. Gunter attended Stanford University and the University of Kansas School of Medicine. He completed medical residencies at the University of Kansas and Johns Hopkins. He is board certified in anatomic pathology, clinical pathology, blood banking and transfusion medicine. He completed an immunology fellowship at the US National Institutes of Health. His work experience has included the FDA as a Medical Officer in the Center for Biologics, Deputy Director of the FDA Division of Cell and Gene Therapy, Assistant Professor at Children’s National Medical Center in Washington, DC and several leadership positions in private industry (including Transkaryotic, ViaCell and Hospira).
He is currently Chief Medical Officer for Cell Medica and is based in Houston, TX. He has been active in the International Society for Cellular Therapy (ISCT) and is currently Past President and Advisory Board Chair of ISCT. He serves or has served on the scientific advisory boards of four other companies. He is a grant reviewer for the California Institute of Regenerative Medicine (CIRM). He is an active member of several other scientific societies including AABB, International Society for Stem Cell Research, American Society of Hematology, and American Society for Blood and Marrow Transplantation. He previously served on the FDA Cell, Tissue and Gene Therapy Advisory Committee. Kurt attended Stanford University and the University of Kansas.
Randall D. Ostroff, MD (Anesthesiologist)
Dr. Randall Ostroff is a board-certified anesthesiologist with more than 25 years of clinical practice experience, predominately in private practice. After completing his BS at the University of Illinois at Urbana-Champaign, he received his Medical Degree at The Chicago Medical School. He completed his residency in anesthesiology at Michael Reese Hospital in Chicago and subsequently held the position of Chairman & Medical Director, Department of Anesthesiology at MacNeal Hospital in Berwyn, IL for nearly 20 years.
Dr. Ostroff also has considerable experience in the pharmaceutical industry, having served eight years as a Global Medical Director for Abbott, where his accomplishments, among others, included two Presidents Awards. During the past 10 years, he has served as a consultant to several pharma companies, most recently Paion AG, which is the developer of remimazolam, a benzodiazepine with unique metabolism recently having completed phase III trials targeted for a conscious sedation indication in the U.S.
Pradeep Tyagi, PhD (Associate Professor)
Dr. Pradeep Tyagi is an Associate Professor in the Department of Urology at the University of Pitsburg. Dr. Tyagi’s research interests include understanding the action of neutrophins and cytokines in urological diseases through genetic and pharmacological manipulation, as well as the use of urinary proteomics to assist in patient selection and treatment monitoring in patients with overactive bladder and interstitial cystitis using Luminex technology. Dr. Tyagi is a member of the American Urological Association (AUA) and the Indian Pharmacology Society, is Principal Investigator on NIH projects, holds multiple patents, and is a published author of several articles and abstracts. In addition, Dr. Tyagi sits on the editorial boards of several journals, including Frontiers of Pharmacology, the Journal of Nanopharmaceutics and Drug Delivery, and the World Journal of Clinical Urology.